血清胸苷激酶1对Ⅳ期结肠癌化疗疗效评估的临床价值  

Clinical Value of Serum Thymidine Kinase 1 in the Evaluation of Chemotherapy for Stage Ⅳ Colon Cancer

作　　者：孙华威[1] 梅梅[1] 刘媛媛[1] 刘雪竹[1] SUN Huawei;MEI Mei;LIU Yuanyuan;LIU Xuezhu(Chemoradiotherapy Department,The First Affiliated Hospital of Jiamusi University,Jiamusi Heilongjiang 154002,China)

机构地区：[1]佳木斯大学附属第一医院放化疗科,黑龙江佳木斯154002

出　　处：《继续医学教育》2018年第8期81-83,共3页Continuing Medical Education

摘　　要：目的研究血清胸苷激酶1对Ⅳ期结肠癌化疗疗效评估的临床价值。方法本次研究选取的研究对象为2016年3月1日—2017年2月28日在我院进行治疗的Ⅳ期结肠癌患者80例(观察组)和同期的健康体检者60例(对照组)。检测两组受检者的血清胸苷激酶1水平,并组间对比阳性率,分析血清胸苷激酶1与临床病理特征、化疗疗效之间的关系。结果观察组Ⅳ期结肠癌患者的血清胸苷激酶1、阳性率高于对照组,差异具有统计学意义(P<0.05),且血清胸苷激酶1和患者的ECOG评分存在相关性(P<0.05);化疗后,病情缓解的Ⅳ期结肠癌患者血清胸苷激酶1低于化疗前,差异具有统计学意义(P<0.05);进展组患者的血清胸苷激酶1较化疗前上升,差异具有统计学意义(P<0.05);化疗后,两组研究对象的血清胸苷激酶1含量比较,差异具有统计学意义(P<0.05)。结论监测血清胸苷激酶1水平能够较好的评估Ⅳ期结肠癌患者的化疗疗效,临床应用价值高。Objective To study the clinical value of serum thymidine kinase 1 in evaluating the efficacy of chemotherapy for stage IV colon cancer. Methods the subjects of this study were 80 patients with stage Ⅳ colon cancer from March 1, 2016 to February 28, 2017 in our hospital, and 60 healthy controls during the same period. The serum thymidine kinase 1 level of the two groups was detected, and the positive rate between the two groups was compared. The relationship between serum thymidine kinase 1 and clinicopathological characteristics and chemotherapy efficacy was analyzed. Results The serum thymidine kinase 1 and positive rate in the observation group were higher than those in the control group, the difference was statistically significant（P〈0.05）. There was a correlation between serum thymidine kinase 1 and ECOG score, the difference was statistically significant（P〈0.05）. After chemotherapy, the serum thymidine kinase 1 level in patients with stage Ⅳ colon cancer was significantly lower than that before chemotherapy, the difference was statistically significant（P〈0.05）. The serum thymidine kinase 1 in the progression group increased compared with that before chemotherapy, and the difference was statistically significant（P〈0.05）. After chemotherapy, there was a significant difference in serum thymidine kinase 1 between the two groups, the difference was statistically significant（P〈0.05）. Conclusion The level of serum thymidine kinase 1 can be used to evaluate the efficacy of chemotherapy in stage Ⅳ colon cancer patients with high clinical value.

关 键 词：Ⅳ期结肠癌 血清胸苷激酶1 化疗疗效 临床价值 

分 类 号：R735[医药卫生—肿瘤]